These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 26952656)
1. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience. De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant-intensified treatment for rectal cancer: time to change? Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984 [TBL] [Abstract][Full Text] [Related]
4. Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes. De Felice F; Llange K; Rubini F; Bulzonetti N; Caiazzo R; Musio D; Tombolini V Clin Colorectal Cancer; 2018 Mar; 17(1):e77-e81. PubMed ID: 29113729 [TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140 [TBL] [Abstract][Full Text] [Related]
6. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210 [TBL] [Abstract][Full Text] [Related]
9. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis. Ye W; Shi L; Qian L; Sun Y; Sun X Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909 [TBL] [Abstract][Full Text] [Related]
11. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572 [TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome. Hess V; Winterhalder R; von Moos R; Widmer L; Stocker P; Jermann M; Herrmann R; Koeberle D Clin Colorectal Cancer; 2017 Sep; 16(3):240-245. PubMed ID: 27687815 [TBL] [Abstract][Full Text] [Related]
14. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L; Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473 [TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M J BUON; 2013; 18(2):385-90. PubMed ID: 23818350 [TBL] [Abstract][Full Text] [Related]
16. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731 [TBL] [Abstract][Full Text] [Related]
17. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related]
18. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356 [TBL] [Abstract][Full Text] [Related]
19. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838 [TBL] [Abstract][Full Text] [Related]
20. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Vestermark LW; Jensen HA; Pfeiffer P Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]